### Sunday, 17 September, 2017

**Room**: Sunset Foyer  

13:00-18:30 **Registration**

15:00-15.10 **Opening remarks**  
Gregory A. Poland, Editor in Chief, Vaccine and Mayo Clinic, USA

15:10-17:00 **PLENARY SESSION 1**  
Session Chair: Gregory A. Poland, Editor in Chief, Vaccine and Mayo Clinic, USA

15.10-16.00 [PL01] **Investigational vaccines that should be licensed: 1. Pertussis 2. Malaria**  
Winner of the Schneerson-Robbins Prize – Rachel Schneerson, National Institutes of Health, USA (Retired)

16.00-16.50 [PL02] **Investigational vaccines that should be licensed: 1. Meningococcus group B/E. coli K1 2. Haemophilus influenza type a**  
Edward Jenner and Vaccine Journal Prize – John B Robbins, National Institutes of Health, USA (Retired)

**Room**: Sunset I-V  
17:00-18:30 **Drinks Reception and Posters Session I**

### Monday, 18 September, 2017

**Room**: Sunset I-V  
08:30-10:30 **PLENARY SESSION 2: Zika Vaccines**  
Session Chair: Gregory A. Poland, Mayo Clinic, USA

08:30-09.10 [PL03] **From A(edes) to Z(ika): Where are we in our vaccine development efforts?**  
Gregory A. Poland - Editor in Chief, Vaccine and Mayo Clinic, USA

09.10-09.50 [PL04] **Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans**  
Daniela Weiskopf, La Jolla Institute for Allergy and Immunology, USA

09.50-10.30 [PL05] **Zika Vaccine Accelerated Clinical Development**  
Grace L Chen, National Institutes of Health, USA

**Room**: Sunset Pavilion/Terrace  
10:30-11:00 **Refreshment break**

**Room**: Sunset I-V  
11:00-13:00 **ORAL SESSION 1: Vaccines Against Emerging Viruses**  
Session Chairs: Tony Fooks & Ab Osterhaus

11:00-11:30 [INV01] **How to deliver new vaccines under very short timelines: the ZAPI project**  
Jean Christophe Audonnet, Boehringer Ingelheim Animal Health, France

11:30-11:45 [O1.01] **Efficient immunization and full protection from lethal challenge by PLLAV-YF17D, a novel thermotolerable and readily scalable plasmid-launched life-attenuated yellow fever vaccine candidate produced in E. coli**  
K. Dallmeier*, N. Mishra¹, R.E. Marques¹-², J. Ae-Choi³, D.B. Kum¹, L. Sanchez Felipe⁴, J.G. Julander³, J. Neyts¹  
¹University of Leuven, Belgium, ²Laboratório Nacional de Biociências (LNBio), Brazil, ³Utah State University Logan, USA

11:45-12:00 [O1.02] **Development of a Novel Vaccine for Zika**  
F. Guirakhoo*, A. Domi¹, N. McCurley¹, R. Basu¹, M. Hellerstein¹, H. Robinson¹, A. Brault²  
²Geovax, USA, ²CDC, USA

12:00-12:15 [O1.03] **Evaluation of candidate chimeric influenza hemagglutinin vaccines for induction of broad immunity within the influenza virus H1N1 subtype**  
S. Zaiser¹, Z. Li¹, P. Shang², P. Katwai¹, Y. Li¹, S.Y. Sunwoo¹, J.A. Richt³, Y. Fang³, B. He², V.C. Huber*¹  
¹University of South Dakota, USA, ²University of Georgia, USA, ³Kansas State University, USA

12:15-12:30 [O1.04] **Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:30-12:45  | [O1.05] Determining the effects of JUNV L Polymerase Mutations on Replication Activity and Regulation  
              S.J. Hallam*1, J.T. Manning1, T. Koma2, S. Paessler1  
              1University of Rochester, USA, 2The Scripps Research Institute, USA |
| 12:45-13:00  | [O1.06] An mRNA-based vaccine technology for next generation prophylactic vaccines  
              CureVac AG, Germany |
| Room         | Sunset Pavilion/Terrace                                                  |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-14:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>Room</td>
<td>Sunset V</td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Author and Reviewer Workshop</td>
</tr>
<tr>
<td>Room</td>
<td>Sunset I-IV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:30-16:30  | BREAKOUT SESSION 2: Novel Vaccines against Respiratory Pathogens    
              Session Chair: Danny Altmann                                         |
| 14:30-15.00  | [INV02] Gut microbiota is associated with the immune response to HIV-1 envelope vaccination in newborn rhesus macaques.  
              Sallie Permar1,2,3, University of California at Davis, USA,  
              2University of North Carolina at Chapel Hill, USA, 3Duke University Medical Center, USA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:00-15:15  | [B2.01] Tim-3, galectin-9 and activation of human NK cells by Trypanosoma cruzi  
              A. Zucchi, N. Segueni*, C. Truyens, Université Libre de Bruxelles, Belgium |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
              R.H.M. Raeven1,2,3, J. Brummelman1,2, J.L.A. Penning1, W. van Eden1, W. Jiskoot1, E. van Riet1,  
              C.A.C.M. van Els2, G.F.A. Kersten1,2, W.G.H. Han2, B. Metz1,  
              1Intravacc, The Netherlands, 2National Institute for Public Health and the Environment, The Netherlands,  
              3Utrecht University, The Netherlands, 4Leiden Academic Centre for Drug Research, The Netherlands |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:30-15:45  | [B2.03] The field evaluation of three subunit vaccine formulas to protect dairy calves against respiratory tract infections caused by Gram-negative bacteria*  
              J. Bajzert1, A. Rzasa1, M. Kuczaj1, P. Jawor1, T. Stefaniak1, W. Jachymek1, S. Przybyl1, C. Lugowski2, F. Jelen3, R. Kolodziejczyk3,  
              1Wroclaw University of Environmental and Life Sciences, Poland, 2Institute of Immunology and Experimental Therapy Polish Academy of Science, Poland, 3Pure Biologics Ltd., Poland |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:45-16:00  | [B2.04] Preclinical assessment of virus-like particle-associated pre- and post-fusion forms of respiratory syncytial virus F protein in maternal vaccination  
              J.C.G. Blanco1, L.M. Pletneva1, L. McGinness2, R.O. Oue1, M.C. Patel1, M.S. Boukhvalova1, T.G. Morrison2  
              1Sigmovir Biosystems Inc., USA, 2University of Massachusetts Medical School, USA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:00-16:15  | [B3.01] Vaccination against Neisseria gonorrhoeae in a mouse model  
              M.W. Russell, University at Buffalo, USA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:15-16:30  | [B3.02] Novel TLR adjuvant system elicits unique immune responses in Q fever vaccine candidates  
              A. Gilkes1, T.J. Albin1, S. Manna1, J.K. Tom1, S. Ruiz3, C. Rooney2, A. Jain3, A. Jasinskas3, M. Supnet1, A.M. Burkhardt1  
              1University of California, Irvine, USA, 2The United States Army Medical Research Institute for Infectious Diseases, USA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:30-16:45  | [B3.03] Reprogramming the innate immune system against bacterial pathogens using a biomaterial based vaccine  
              E. Doherty, Harvard University, USA, Boston Children’s Hospital and Harvard Medical School, USA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:45-17:00  | [B3.04] Pivotal role of cellular necrosis in residual cytotoxicity of a recombinant vaccine against Clostridium Difficil  
              L. Hong, Merck, USA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:00-16:15 | [B2.05] Induction of protective immune responses against group A streptococcus following vaccination with lyophilized liposomes containing surface-expressed peptide and encapsulated carrier protein  
M. Zaman*, V. Ozberk, S. Eskandari  
*Institute for Glycomics, Griffith University, Australia |
| 16:15-16:30 | [B2.06] Vaccination targeting the 12 protease cleavage sites during ARV treatment improved CD4 counts of SIVmac251 infected rhesus monkeys  
M. Luo1,2, J. Pinto3, M. Nykoluk1, C. Czarnecki1, J. Whitney1, M. Alonso1, T.B. Ball1,2, G. Kobinger1,2, F.A. Plummer1,2  
1National Microbiology Laboratory, Canada,  
2University of Manitoba, Canada,  
3University of Santiago de Compostela, Spain,  
4Harvard Medical School, USA |
| 16:50-17:00 | [B3.05] Development of a Treponema denticola targeting chimeric vaccine for periodontal disease  
N.S.O. O’Bier1, L.D.O. Oliver1, A.L.H. Hatke1, D.T.P. Patel1, J.R.I. Izac1, R.T.M. Marconi1,2  
1Department of Microbiology and Immunology, USA,  
2Virginia Commonwealth University, USA |
| 17:00-18:00 | ORAL SESSION 4: New Influenza Vaccines  
Session Chair: Kathy Neuzil |
| 17:00-17:30 | [INV04] From bench to bedside: the challenge to develop better influenza vaccines  
Ruben Donis, Biomedical Advanced Research and Development Authority |
| 17:30-18:00 | [O4.01] Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines.  
A. Nogales*, M. L. DeDiego, L. Rodriguez, D. J. Topham, L. Martinez-Sobrido  
*University of Rochester, USA |
| 18:00-18:30 | [O4.02] The antibody response to influenza vaccine shows that humans have the capacity for wide breadth of protection  
S. Delagrave1, T. Alefantis1, I. Nunez2, S. Mundle1, I. Ustyugova1, T. Strugnell1, J. DiNapoli1, M. Carlock2, S. Anderson1, T.U. Vogel1  
1Sanofi Pasteur, USA,  
2Center for Vaccines and Immunology, USA,  
3University of Georgia, USA,  
4University of Pittsburgh, USA |
| 18:30-19:00 | [INV05] Extracellular nucleic acids as a vaccine tool and an immune modulator  
Ken J. Ishii1,2,1National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan,  
2Osaka University, Japan |
| 19:00-20:00 | Drinks Reception and Poster Session II |

---

**Tuesday, 19 September, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 08:30-10:30 | PLENARY SESSION 3: HIV Vaccines  
Session Chairs: Robert Chen & Gregory A. Poland |
| 08:30-09:10 | [PL06] Progress toward a neutralizing antibody-based HIV vaccine  
Dennis R. Burton1,2,1The Scripps Research Institute, USA,  
2Ragon Institute of MGH, MIT and Harvard, USA |
| 09:10-09:50 | [PL07] Germline-targeting vaccine design for HIV  
William Schief, The Scripps Research Institute, USA, IAVI, USA |
| 09:50-10:30 | [PL08] Extracellular nucleic acids as a vaccine tool and an immune modulator  
Ken J. Ishii1,2,1National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan,  
2Osaka University, Japan |
| 10:30-11:00 | Refreshment break |
| 11:00-12:00 | ORAL SESSION 5: Vaccines against emerging biothreats  
Session Chair: Danny Altmann & Lisa Shollenberger |
| 11:00-11:30 | [INV05] Ebola virus: Comparison of naturally acquired and vaccine induced immunity  
Miles W. Carroll, Public Health England, UK |
| 11:30-12:00 | [O5.01] Advances in next generation anthrax vaccines: development of capsule conjugate and live attenuated vaccines  
A.M. Friedlander1,2 |
10:45-12:00 | [05.02] A novel intranasal subunit vaccine for Plague  
T. Shute*1, C. D’Arco2, A.A. McCormick2, R.J. Dattwyler3, P.M. Arnaboldi1  
1New York Medical College, USA, 2Uniformed Services University of the Health Sciences, USA

12:00-13:00 | Meet the Editors Speed Review Roundtable - All AE's  
Room | Sunset Pavilion/Terrace
13:00-14:30 | Lunch

13:30-14:30 | Roundtable  
Session Chairs: Ab Osterhaus and Gregory A. Poland

14:30-16:00 | BREAKOUT SESSION 6: Vaccine Safety  
Session Chairs: Robert Chen & Steve Jacobsen  
Room | Sunset I-IV

14:30-15:00 | [INV06] A global vaccine safety data network: rationale, progress and remaining challenges  
Steve Black, Cincinnati Children’s Hospital, USA  

15:00-15:15 | [B6.01] Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink project  
R.C. Hechter*1, L. Qian1, S. Tartof2, L. Sy3, N.P. Klein1, J. Glanz1, C. Mercado1, A. Naleway1, E.R. Vickers2, S.J. Jacobsen1  
1Kaiser Permanente, USA, 2Marshfield Clinic Research Foundation, USA

15:15-15:30 | [B6.02] Characterization of the genetic compatibility between Rift Valley fever virus MP-12 strain and Arumowot virus for the reassortant risk analysis  
H.J. Hallam*, L. Lokugamage, T. Ikegami  
The University of Texas Medical Branch in Galveston, USA

15:30-15:45 | [B6.03] HLA-Cw10 is strongly associated with tetanus vaccine and rabies vaccine cutaneous adverse drug reactions  
S. Yan  
Fudan University, China

15:45-16:00 | [B6.04] Human papillomavirus vaccination in pregnancy and adverse pregnancy outcomes  
A.T. Bukowski*1,2, R.N. Chang1, A.M. Conlin1, G.R. Gumbs1, C.J. Sevick2  
1The Henry M. Jackson Foundation for the Advancement of Military Medicine, USA, 2Naval Health Research Center, USA

16:00-16:15 | [B6.05] HPV Vaccine in Pregnancy and Adverse Infant Outcomes  
R. Chang*1,2, J.A. Bukowski1,2, A. Conlin1,2, G. Gumbs1,2, C. Sevick1,2  
1The Henry M. Jackson Foundation for the Advancement of Military Medicine, USA, 2Naval Health Research Center, USA

16:00-16:15 | [B7.02] A new potent adjuvant / immunomodulatory protein of Trypanosoma cruzi acts through TLR4  
S. Ait Djebbara*1, K. Otis1,2, P. Lehebel1,3, V. Flamand1, N. Segueni1, C. Truyens1  
1Université libre de Bruxelles (ULB), Belgium, 2INRS-Institut Armand-Frappier, Canada, 3Scientific Institute of Public Health (WIV-ISP), Belgium

16:15-16:30 | General Q&A  
Room | Sunset Pavilion/Terrace

16:30-17:00 | Refreshment break

17:00-18:00 | ORAL SESSION 8: New Vaccines - Old Diseases
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00-17:30</td>
<td>[INV08] New Polio Vaccines for the Post-Eradication Era</td>
<td>John F. Modlin, Gates Foundation, USA</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>[O8.01] Safety and immunogenicity of the recombinant BCG vaccine VPM1002, in HIV-unexposed newborn infants in South Africa</td>
<td>A.G. Loxton(^1), L. Grode(^2), A. Gutschmidt(^3), C. Meller(^3), B. Eisele(^3), G. vd Spuy(^3), S.H.E. Kaufmann(^3), A.C. Hesselg(^1), G. Walzl(^1), M. Cotton(^1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(^1)Stellenbosch University, South Africa, (^2)VPM, Germany, (^3)MPIIB, Germany</td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>[O8.02] A Vaccinomics Approach Using GWAS Results to Develop a Novel Measles-Mumps-Rubella (MMR) Vaccine</td>
<td>J. G. Ovsyannikova(^*), I. H. Haralambieva, R. B. Kennedy, G. A. Poland  Mayo Clinic, United States</td>
</tr>
<tr>
<td>19:30-22:00</td>
<td>Conference Dinner at San Diego Zoo (Ticket Required)</td>
<td>Coach departs for dinner at 18:45 from the lobby of the hotel</td>
</tr>
</tbody>
</table>

---

### Wednesday, 20 September, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:30</td>
<td>YIP Session</td>
<td></td>
</tr>
<tr>
<td>Room</td>
<td>Sunset I-V</td>
<td></td>
</tr>
<tr>
<td>08:30-10:30</td>
<td>PLENARY SESSION 4 - Systems Biology and Vaccines</td>
<td>Session Chair: Gregory A. Poland</td>
</tr>
<tr>
<td>Room</td>
<td>Sunset I-V</td>
<td></td>
</tr>
<tr>
<td>08:30-09.10</td>
<td>[PL09] Differences in T cell responses to Bordetella Pertussis in adults as a function of whole cell versus acellular childhood vaccination</td>
<td>Alex Sette, La Jolla Institute for Allergy and Immunology, USA</td>
</tr>
<tr>
<td>Room</td>
<td>Sunset Pavilion/Terrace</td>
<td></td>
</tr>
<tr>
<td>09.10-09.50</td>
<td>[PL10] Systems immunology of Mycobacterium tuberculosis infection</td>
<td>Bjorn Peters, La Jolla Institute for Allergy and Immunology, USA</td>
</tr>
<tr>
<td>Room</td>
<td>Sunset I-V</td>
<td></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Refreshment break</td>
<td></td>
</tr>
<tr>
<td>Room</td>
<td>Sunset I-V</td>
<td></td>
</tr>
<tr>
<td>11:00-12:30</td>
<td>ORAL SESSION 9: Synthetic Biology and Vaccines</td>
<td>Session Chair: Linda Lua</td>
</tr>
<tr>
<td>Room</td>
<td>Sunset I-V</td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>[INV09] Synthetic Approaches to Viral Vaccine Development</td>
<td>Phil R. Dormitzer, Pfizer Vaccine Research and Development, USA</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>[O9.01] Development of an multi-protein based chimeriotope vaccine for human Lyme disease</td>
<td>J. Izac(^*), L. Oliver, C. Earnhart, R. Marconi  Virginia Commonwealth University, USA</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>[O9.02] The importance of RSV F protein conformation in stimulation of neutralizing antibody titers in mice previously infected with RSV</td>
<td>T.G. Morrison(^*), L.W. McGinnes(^1), J. Blanco(^2), M. Schmidt(^1), S. Kenward(^1), R. Woodland(^1)  (^1)University of Massachusetts Medical School, USA,  (^2)Sigmovir Biosystems, Inc., USA</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>[O9.03] Characterization of the human antibody response to the 4CMenB meningococcal vaccine: detailed insights from structural biology</td>
<td>J. Lopez-Sagasta(^1), A. Liguori(^1), L. Dello Iacono(^1), G. Maruggi(^2), F. Bianchi(^1), L. Santini(^1), P. Lo Surdo(^1), M. Pizza(^1), E. Malito(^1), M.J. Bottomley(^<em>)(^1)  (^1)GSK Vaccines Srl, Italy,  (^2)The Scripps Research Institute, USA,  (^</em>)GSK, USA</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>[O9.04] Synthetic biology for molecular and bioprocess design of virus-like particle vaccine</td>
<td>L.H.L. Lua(^*), A.P.J. Middelberg(^2)  The University of Queensland, Australia, The University of Adelaide, Australia</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Closing Session</td>
<td></td>
</tr>
<tr>
<td>Room</td>
<td>Sunset V</td>
<td></td>
</tr>
<tr>
<td>14:00-17:00</td>
<td>Special workshop- The Intersection of Digital Health and Vaccines</td>
<td>Bruce Lee, Johns Hopkins, USA</td>
</tr>
</tbody>
</table>